DIPHERELINE

This brand name is authorized in Australia, Ecuador, Estonia, Hong Kong SAR China, Lithuania, Poland, Romania, Singapore.

Active ingredients

The drug DIPHERELINE contains one active pharmaceutical ingredient (API):

1	Triptorelin UNII 9081Y98W2V - TRIPTORELIN
	Triptorelin is a decapeptide analogue of GnRH which initially stimulates release of pituitary gonadotropins.
	Read more about Triptorelin

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
DIPHERELINE Powder and solvent for suspension for injection	MPI, EU: SmPC	Pharmaceutical Benefits Scheme (AU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L02AE04	Triptorelin	L Antineoplastic and immunomodulating agents → L02 Endocrine therapy → L02A Hormones and related agents → L02AE Gonadotropin releasing hormone analogues
Discover more medicines within L02AE04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	5297T, 9378N, 9379P
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	4972-MEE-0220, 5168-MEE-0620
EE	Ravimiamet	1012868, 1040397, 1400421, 1818604, 1822968
HK	Department of Health Drug Office	47655, 51941, 53473, 62788
LT	Valstybinė vaistų kontrolės tarnyba	1002990, 1003523, 1005529, 1008105, 1086457, 1087838, 1091101
PL	Rejestru Produktów Leczniczych	100094400, 100103027, 100103719, 100242600
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W55725001, W55726002, W55727001, W62618001
SG	Health Sciences Authority	14634P, 14635P